Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes

Gustavo Arango-Argoty, Damian E. Bikiel, Gerald J. Sun, Elly Kipkogei, Kaitlin M. Smith, Sebastian Carrasco Pro, Etai Jacob
doi: https://doi.org/10.1101/2024.01.31.24302104
Gustavo Arango-Argoty
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gustavo.arango{at}astrazeneca.com etai.jacob{at}astrazeneca.com
Damian E. Bikiel
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald J. Sun
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elly Kipkogei
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaitlin M. Smith
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Carrasco Pro
2Life Sciences, Tempus AI, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etai Jacob
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gustavo.arango{at}astrazeneca.com etai.jacob{at}astrazeneca.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Modern clinical trials can capture tens of thousands of clinicogenomic measurements per individual. Discovering predictive biomarkers, as opposed to prognostic markers, is challenging when using manual approaches. To address this, we present an automated neural network framework based on contrastive learning—a machine learning approach that involves training a model to distinguish between similar and dissimilar inputs. We have named this framework the Predictive Biomarker Modeling Framework (PBMF). This general-purpose framework explores potential predictive biomarkers in a systematic and unbiased manner, as demonstrated in simulated “ground truth” synthetic scenarios resembling clinical trials, well-established clinical datasets for survival analysis, real-world data, and clinical trials for bladder, kidney, and lung cancer. Applied retrospectively to real clinicogenomic data sets, particularly for the complex task of discovering predictive biomarkers in immunooncology (IO), our algorithm successfully found biomarkers that identify IO-treated individuals who survive longer than those treated with other therapies. In a retrospective analysis, we demonstrated how our framework could have contributed to a phase 3 clinical trial (NCT02008227) by uncovering a predictive biomarker based solely on early study data. Patients identified with this predictive biomarker had a 15% improvement in survival risk, as compared to those of the original trial. This improvement was achieved with a simple, interpretable decision tree generated via PBMF knowledge distillation. Our framework additionally identified potential predictive biomarkers for two other phase 3 clinical trials (NCT01668784, NCT02302807) by utilizing single-arm studies with synthetic control arms and identified predictive biomarkers with at least 10% improvement in survival risk. The PBMF offers a broad, rapid, and robust approach to inform biomarker strategy, providing actionable outcomes for clinical decision-making.

Competing Interest Statement

G.A.-A., D.E.B., G.J.S., E.K., K.M.S., and E.J. are current or former employees of AstraZeneca with stock ownership, interests, and/or options in the company. S.C.P. is an employee of Tempus with stock ownership, interests, and/or options in the company.

Funding Statement

This study was funded by AstraZeneca

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All datasets with human data are publicly available at the following URLs: (1) https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html (2) https://www.nature.com/articles/s41591-018-0134-3

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • 7 more data sets added to the analysis

Data Availability

All human data used are available online at the following URLs: (1) https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html (2) https://www.nature.com/articles/s41591-018-0134-3. Simulation data are available upon reasonable request to authors.

https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html

https://www.nature.com/articles/s41591-018-0134-3

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 07, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes
Gustavo Arango-Argoty, Damian E. Bikiel, Gerald J. Sun, Elly Kipkogei, Kaitlin M. Smith, Sebastian Carrasco Pro, Etai Jacob
medRxiv 2024.01.31.24302104; doi: https://doi.org/10.1101/2024.01.31.24302104
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes
Gustavo Arango-Argoty, Damian E. Bikiel, Gerald J. Sun, Elly Kipkogei, Kaitlin M. Smith, Sebastian Carrasco Pro, Etai Jacob
medRxiv 2024.01.31.24302104; doi: https://doi.org/10.1101/2024.01.31.24302104

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)